$PCRX
Pacira BioSciences, Inc. Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000139681417000015 Filed on May 04, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$69.28M	$65.47M
YoY Change	5.82%	12.27%
Cost Of Revenue	$24.58M	$20.28M
YoY Change	21.22%	15.35%
Gross Profit	$44.70M	$45.20M
YoY Change	-1.09%	10.95%
Gross Profit Margin	64.52%	69.03%
Selling, General & Admin	$42.12M	$37.96M
YoY Change	10.97%	20.77%
% of Gross Profit	94.22%	83.98%
Research & Development	$16.63M	$9.493M
YoY Change	75.2%	59.09%
% of Gross Profit	37.21%	21.0%
Depreciation & Amortization	$3.104M	$3.165M
YoY Change	-1.93%	15.38%
% of Gross Profit	6.94%	7.0%
Operating Expenses	$83.33M	$67.73M
YoY Change	23.04%	23.2%
Operating Profit	-$14.05M	-$2.254M
YoY Change	523.34%	-167.46%
Interest Expense	$2.589M	$1.868M
YoY Change	38.6%	-6.41%
% of Operating Profit
Other Income/Expense, Net	-$5.786M	-$1.568M
YoY Change	269.01%	-22.72%
Pretax Income	-$19.84M	-$3.822M
YoY Change	419.0%	-391.31%
Income Tax	$30.00K	$32.00K
% Of Pretax Income
Net Earnings	-$19.87M	-$3.854M
YoY Change	415.46%	-405.87%
Net Earnings / Revenue	-28.67%	-5.89%
Basic Earnings Per Share	-$0.52	-$0.10
Diluted Earnings Per Share	-$523.7K	-$105.4K
COMMON SHARES
Basic Shares Outstanding	38.00M shares	37.02M shares
Diluted Shares Outstanding		37.02M shares

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$383.7M	$150.0M
YoY Change	155.8%	-3.16%
Cash & Equivalents	$109.0M	$35.03M
Short-Term Investments	$274.7M	$115.0M
Other Short-Term Assets	$6.300M	$9.000M
YoY Change	-30.0%	119.51%
Inventory	$30.31M	$63.74M
Prepaid Expenses
Receivables	$27.70M	$25.90M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$448.0M	$248.6M
YoY Change	80.18%	13.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$102.6M	$95.85M
YoY Change	7.02%	42.62%
Goodwill	$48.83M	$32.78M
YoY Change	48.94%	29.17%
Intangibles
YoY Change
Long-Term Investments		$13.50M
YoY Change		-32.16%
Other Assets	$598.0K	$481.0K
YoY Change	24.32%	-80.22%
Total Long-Term Assets	$152.0M	$142.6M
YoY Change	6.6%	23.68%
TOTAL ASSETS
Total Short-Term Assets	$448.0M	$248.6M
Total Long-Term Assets	$152.0M	$142.6M
Total Assets	$600.0M	$391.2M
YoY Change	53.36%	16.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.373M	$10.48M
YoY Change	-10.6%	88.39%
Accrued Expenses	$34.90M	$29.07M
YoY Change	20.07%	14.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$105.2M
YoY Change	-100.0%	1.06%
Long-Term Debt Due	$800.0K
YoY Change
Total Short-Term Liabilities	$45.65M	$146.1M
YoY Change	-68.76%	7.1%
LONG-TERM LIABILITIES
Long-Term Debt	$266.0M	$0.00
YoY Change
Other Long-Term Liabilities	$10.33M	$11.02M
YoY Change	-6.24%	103.92%
Total Long-Term Liabilities	$10.33M	$11.02M
YoY Change	-6.24%	103.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$45.65M	$146.1M
Total Long-Term Liabilities	$10.33M	$11.02M
Total Liabilities	$329.3M	$165.0M
YoY Change	99.55%	9.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$366.4M	-$312.1M
YoY Change	17.38%	1.05%
Common Stock	$40.00K	$37.00K
YoY Change	8.11%	2.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	0.000 shares	0.000 shares
Shareholders Equity	$270.6M	$226.2M
YoY Change
Total Liabilities & Shareholders Equity	$600.0M	$391.2M
YoY Change	53.36%	16.77%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$19.87M	-$3.854M
YoY Change	415.46%	-405.87%
Depreciation, Depletion And Amortization	$3.104M	$3.165M
YoY Change	-1.93%	15.38%
Cash From Operating Activities	$10.00K	-$3.120M
YoY Change	-100.32%	258.62%
INVESTING ACTIVITIES
Capital Expenditures	$3.616M	$7.053M
YoY Change	-48.73%	-10.43%
Acquisitions
YoY Change
Other Investing Activities	-$140.2M	-$14.82M
YoY Change	846.15%	-283.64%
Cash From Investing Activities	-$143.8M	-$21.88M
YoY Change	557.4%	-11040.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$216.9M	$3.041M
YoY Change	7031.08%	-24.86%
NET CHANGE
Cash From Operating Activities	10.00K	-3.120M
Cash From Investing Activities	-143.8M	-21.88M
Cash From Financing Activities	$216.9M	$3.041M
Net Change In Cash	$216.9M	$3.041M
YoY Change	7031.08%	-24.86%
FREE CASH FLOW
Cash From Operating Activities	$10.00K	-$3.120M
Capital Expenditures	$3.616M	$7.053M
Free Cash Flow	-$3.606M	-$10.17M
YoY Change	-64.55%	16.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001396814
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40093883	shares
CY2017Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	Pacira Pharmaceuticals, Inc.
CY2016Q1	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	120000	USD
CY2017Q1	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	168000	USD
CY2017Q1	pcrx	Collaborative Agreement Fee Payment Period CollaborativeAgreementFeePaymentPeriod	P2Y
CY2013Q4	pcrx	Collaborative Arrangement Agreement Term CollaborativeArrangementAgreementTerm	P5Y
CY2016Q1	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	356000	USD
CY2017Q1	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	206000	USD
CY2016Q1	pcrx	Compensationexpensefromemployeestockpurchaseplan Compensationexpensefromemployeestockpurchaseplan	275000	USD
CY2017Q1	pcrx	Compensationexpensefromemployeestockpurchaseplan Compensationexpensefromemployeestockpurchaseplan	207000	USD
CY2016Q1	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	6856000	USD
CY2017Q1	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	5917000	USD
CY2016Q1	pcrx	Compensationexpensefromstockoptionsnonemployeeawards Compensationexpensefromstockoptionsnonemployeeawards	274000	USD
CY2017Q1	pcrx	Compensationexpensefromstockoptionsnonemployeeawards Compensationexpensefromstockoptionsnonemployeeawards	53000	USD
CY2012Q2	pcrx	Contingent Payment Obligation Established For Sale Of Product In Connection With Acquisition ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition	2000000	USD
CY2017Q1	pcrx	Contract Termination Fee ContractTerminationFee	7100000	USD
CY2017Q1	pcrx	Contract Termination Fee Current Portion ContractTerminationFeeCurrentPortion	3500000	USD
CY2017Q1	pcrx	Contract Termination Fee Long Term Portion ContractTerminationFeeLongTermPortion	1200000	USD
CY2016Q1	pcrx	Conversionofprincipalandequitycomponentofconvertibleseniornotes Conversionofprincipalandequitycomponentofconvertibleseniornotes	0	USD
CY2017Q1	pcrx	Conversionofprincipalandequitycomponentofconvertibleseniornotes Conversionofprincipalandequitycomponentofconvertibleseniornotes	284000	USD
CY2017Q1	pcrx	Debt Instrument Convertible Conversion Premium Shares DebtInstrumentConvertibleConversionPremiumShares	100000	shares
CY2017Q1	pcrx	Debt Instrument Convertible Conversion Value DebtInstrumentConvertibleConversionValue	700000	USD
CY2017Q1	pcrx	Deferred Tax Liability Convertible Senior Notes Conversion DeferredTaxLiabilityConvertibleSeniorNotesConversion	26500000	USD
CY2016Q1	pcrx	Fair Market Valueof Common Stock Issuedfor Convertible Senior Notes Premium FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium	0	USD
CY2017Q1	pcrx	Fair Market Valueof Common Stock Issuedfor Convertible Senior Notes Premium FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium	120466000	USD
CY2016Q4	pcrx	Foreign Property Plantand Equipment Net ForeignPropertyPlantandEquipmentNet	33700000	USD
CY2017Q1	pcrx	Foreign Property Plantand Equipment Net ForeignPropertyPlantandEquipmentNet	37000000	USD
CY2017Q1	pcrx	Goodwill Recordedfor Earn Out Payments GoodwillRecordedforEarnOutPayments	2092000	USD
CY2016Q1	pcrx	Income Lossfrom Continuing Operationsbefore Income Taxes Total IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal	-3822000	USD
CY2017Q1	pcrx	Income Lossfrom Continuing Operationsbefore Income Taxes Total IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal	-19836000	USD
CY2016Q1	pcrx	Income Tax Provision IncomeTaxProvision	100000	USD
CY2017Q1	pcrx	Income Tax Provision IncomeTaxProvision	100000	USD
CY2016	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	customer
CY2017Q1	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	customer
CY2012Q2	pcrx	Payment Obligation Arising Due To First Commercial Sale Of Product In Connection With Acquisition PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition	10000000	USD
CY2016Q1	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	1904000	USD
CY2017Q1	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	2092000	USD
CY2017Q1	pcrx	Settlement Period Convertible Debt Conversion Request SettlementPeriodConvertibleDebtConversionRequest	P40D
CY2017Q1	pcrx	Total Goodwill Recordedfor Earn Out Payments TotalGoodwillRecordedforEarnOutPayments	24900000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7511000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9373000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	29937000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	37510000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27702000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36666000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34900000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	40612000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-30000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-82000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	565207000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	637066000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	0	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	70930000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	0	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-125811000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7400000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8490000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7400000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1022000	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1411000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	153000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	201000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7304000	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7127000	shares
CY2016Q4	us-gaap	Assets Assets	391466000	USD
CY2017Q1	us-gaap	Assets Assets	599962000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	243089000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	447964000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	136683000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	274811000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	19000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	49000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	96000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1554000	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1179000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56984000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35029000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35944000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	108970000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37480952	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40023258	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37480952	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40023258	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	37000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	40000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3753000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19918000	USD
CY2016Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2017Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	759000	USD
CY2016Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	108738000	USD
CY2017Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	265992000	USD
CY2016Q1	us-gaap	Cost Of Revenue CostOfRevenue	20278000	USD
CY2017Q1	us-gaap	Cost Of Revenue CostOfRevenue	24581000	USD
CY2017Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	2500000	shares
CY2017Q1	us-gaap	Debt Instrument Convertible Threshold Consecutive Trading Days DebtInstrumentConvertibleThresholdConsecutiveTradingDays	P30D
CY2017Q1	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	1.3
CY2017Q1	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	20	D
CY2016Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0722
CY2017Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0748
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	595000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	520000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	7487000	USD
CY2017Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	7357000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	100000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	3100000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3165000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3104000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2016Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2017Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-137000	USD
CY2017Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3700000	USD
CY2016Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3721000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	46737000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	48829000	USD
CY2012Q2	us-gaap	Goodwill Goodwill	8000000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3499000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-19320000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3822000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19836000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-323000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-516000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000	USD
CY2016Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	142000	USD
CY2017Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6227000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1056000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	46000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2235000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-356000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-205000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2099000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-967000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-419000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1061000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2917000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3051000	USD
CY2016Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	270000	USD
CY2016Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	300000	USD
CY2017Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	212000	USD
CY2017Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	200000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	1868000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	2589000	USD
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1868000	USD
CY2017Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2589000	USD
CY2016Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	963000	USD
CY2017Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1189000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	1926000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	2380000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7915000	USD
CY2017Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9636000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	31278000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	30311000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	11742000	USD
CY2017Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	12966000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11621000	USD
CY2017Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7709000	USD
CY2017Q1	us-gaap	Inventory Write Down InventoryWriteDown	21300000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	252000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	514000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	172490000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	329329000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	391466000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	599962000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	44838000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	45648000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-21955000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	73026000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3041000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	216856000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-21875000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-143836000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3121000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	6000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-3854000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-19866000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1568000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5786000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	67728000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	83333000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2254000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14050000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	37401000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1207000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	6389000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	8272000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	8063000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	7545000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	5925000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	624000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	598000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	101000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-52000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	101000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-52000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11427000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	10332000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	48000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10000	USD
CY2016Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	11000000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7053000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3616000	USD
CY2016Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	67843000	USD
CY2017Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	180342000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9277000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6252000	USD
CY2016Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2017Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	345000000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	54925000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	42214000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3041000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	852000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	138526000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	143183000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	101016000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	102571000	USD
CY2016Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
CY2017Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	117712000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9493000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16632000	USD
CY2016Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	1085000	USD
CY2017Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	1223000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-346238000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-366391000	USD
CY2016Q1	us-gaap	Revenues Revenues	65474000	USD
CY2017Q1	us-gaap	Revenues Revenues	69283000	USD
CY2016Q1	us-gaap	Royalty Revenue RoyaltyRevenue	616000	USD
CY2017Q1	us-gaap	Royalty Revenue RoyaltyRevenue	652000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	64502000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	68425000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37957000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42120000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8490000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7400000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	22.56
CY2017Q1	us-gaap	Share Price SharePrice	45.6
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.85
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	136653000	USD
CY2017Q1	us-gaap	Short Term Investments ShortTermInvestments	274729000	USD
CY2017Q1	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2480000	shares
CY2017Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2017Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	120466000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	852000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	218976000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	270633000	USD
CY2016Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	66000	USD
CY2017Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	96000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2017Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37020000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37998000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37020000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37998000	shares

Files In Submission

Name	View Source	Status
0001396814-17-000015-index-headers.html	Edgar Link	pending
0001396814-17-000015-index.html	Edgar Link	pending
0001396814-17-000015.txt	Edgar Link	pending
0001396814-17-000015-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
paciralogoa04.jpg	Edgar Link	pending
pcrx-20170331.xml	Edgar Link	completed
pcrx-20170331.xsd	Edgar Link	pending
pcrx-20170331_cal.xml	Edgar Link	unprocessable
pcrx-20170331_def.xml	Edgar Link	unprocessable
pcrx-20170331_lab.xml	Edgar Link	unprocessable
pcrx-20170331_pre.xml	Edgar Link	unprocessable
pcrx-33117xex101.htm	Edgar Link	pending
pcrx-33117xex102.htm	Edgar Link	pending
pcrx-33117xex311.htm	Edgar Link	pending
pcrx-33117xex312.htm	Edgar Link	pending
pcrx-33117xex321.htm	Edgar Link	pending
pcrx-33117xex322.htm	Edgar Link	pending
pcrx-3312017x10xq.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira BioSciences, Inc. Stock $pcrx

2017 Q1 Form 10-Q Financial Statement

#000139681417000015 Filed on May 04, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira BioSciences, Inc. Stock $pcrx

2017 Q1 Form 10-Q Financial Statement

#000139681417000015 Filed on May 04, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira BioSciences, Inc. Stock $pcrx